M2S Inc., an industry leader in medical image management and analysis (http://m2s.com/content/technology), has released new auto blinding technology for the DICOM Armorcar (DAC). M2S's DAC image transfer technology (http://m2s.com/content/dicom-armorcar) has revolutionized the way medical images are transported between sites, core labs and clinical trial sponsors. The newest version of the DAC, which helps provide better support for clinical trial customers, has added the ability for automatic study blinding of patient information in DICOM image files, as well as created the capability to send data between institutions automatically.
The DAC, with its ability to support all standard DICOM modalities, transfers image data securely in its original digital DICOM format for immediate, real-time QC assessment and query
generation/resolution. In addition to its preservation of data integrity, the DAC provides incredible timesavings and eliminates the immense costs associated with storing data on CDs and
shipping them via courier, a standard practice in the industry today.
The DAC is the first system designed specifically to address these significant issues, and the expansion of its global integration will allow clinical trial sponsors to utilize its power
to manage their large international trials more efficiently and cost-effectively than ever before. DACs have already been installed and implemented in over 250 institutions in the U.S.A.,
as well as a growing number in Europe, South America, and Asia.
M2S is a pioneer in image management services and technology, and is a recognized innovator in imaging core lab services for clinical trials (http://m2s.com/content/providing-medical-data-and-image-management-services-health-care%2C-pharmaceutical%2C-biotech%2C-a).
For the past 15 years, the company has worked with many of the world's leading academic centers, pharmaceutical companies, and medical device manufacturers, managing, under protocol,
millions of images from around the globe. M2S develops image-based systems and protocols that reduce time, cost, and uncertainty in clinical trials for the pharmaceutical, biotech, and
medical device industries.